http://medicalxpress.com/ en-us Medical Xpress internet news portal provides the latest news on Health and Medicine. Research presented at Digestive Disease Week (DDW) explores pharmaceutical advances for treating irritable bowel syndrome with diarrhea (IBS-D) and hepatitis C. http://medicalxpress.com/news/2013-05-pharmaceutical-advances-options-health-outcomes.html Diseases, Conditions, Syndromes Mon, 20 May 2013 09:10:55 EST news288259848 (HealthDay)—Sofosbuvir seems to be a promising treatment option for patients with chronic hepatitis C virus (HCV) infection, according to two studies published online April 23 in the New England Journal of Medicine to coincide with presentation at The International Liver Congress, the annual meeting of the European Association for the Study of the Liver, held from April 24 to 28 in Amsterdam. http://medicalxpress.com/news/2013-04-sofosbuvir-chronic-hepatitis-infection.html Diseases, Conditions, Syndromes Tue, 23 Apr 2013 13:10:04 EST news285940342 National Institutes of Health (NIH) scientists studying an emerging coronavirus have found that a combination of two licensed antiviral drugs, ribavirin and interferon-alpha 2b, can stop the virus from replicating in laboratory-grown cells. These results suggest that the drug combination could be used to treat patients infected with the new coronavirus, but more research is needed to confirm this preliminary finding. The study appears in the April 18, 2013, issue of Scientific Reports. http://medicalxpress.com/news/2013-04-treatment-coronavirus-early-lab.html Diseases, Conditions, Syndromes Thu, 18 Apr 2013 05:00:02 EST news285437011 (HealthDay)—For untreated patients with hepatitis C virus (HCV), treatment with an oral nucleotide inhibitor of HCV polymerase, sofosbuvir, plus ribavirin seems effective for genotypes 1, 2, and 3; and the HCV NS3 protease inhibitor ABT-450, combined with low-dose ritonavir (ABT-450/r) plus the nonnucleoside NS5B polymerase inhibitor ABT-333 and ribavirin, seems effective for genotype 1, according to two studies published in the Jan. 2 issue of the New England Journal of Medicine. http://medicalxpress.com/news/2013-01-interferon-free-therapies-hep-virus.html Diseases, Conditions, Syndromes Thu, 03 Jan 2013 11:00:01 EST news276431532 Treating chronic hepatitis C infection with antiviral drugs could halve the risk of developing the most common form of liver cancer, in some cases, indicates an analysis of the published research in one of the new BMJ Open Editions. http://medicalxpress.com/news/2012-10-antiviral-therapy-halve-liver-cancer.html Diseases, Conditions, Syndromes Mon, 22 Oct 2012 18:30:04 EST news270137112 Abbott Laboratories said Monday that its experimental hepatitis C drug regimen cured 99 percent of patients in a midstage study with the most common and hardest-to-treat type of the disease. http://medicalxpress.com/news/2012-10-abbott-labs-hepatitis-drug.html Medications Mon, 15 Oct 2012 11:51:10 EST news269520664 (HealthDay)—For patients with hepatitis C virus (HCV) treated with pegylated interferon-alpha and ribavirin (P/R), drinking patterns and the amount of alcohol consumed before treatment do not impact treatment success, according to a study published in the October issue of Hepatology. http://medicalxpress.com/news/2012-10-prior-alcohol-consumption-impair-hcv.html Diseases, Conditions, Syndromes Thu, 11 Oct 2012 17:50:06 EST news269194502 Targeted multi-drug treatments for hepatitis C patients that could stop the virus in its tracks have come a step closer, thanks to researchers at the University of Leeds, UK. http://medicalxpress.com/news/2011-06-drugs-block-hepatitis-virus-tracks.html Diseases, Conditions, Syndromes Tue, 28 Jun 2011 10:17:09 EST news228474968